EGFR Gene Mutation clinical trials at UCSF

• Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

  open to eligible people ages 18 years and up

  This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and/or bad, it has on EGFR-mutated lung cancer.

  San Francisco, California

Last updated: May 17, 2021